Beijing Puci Pharmaceuticals Enters Exclusive Commercialization Agreement with Jichuan Pharmaceutical for Pumecitinib Nasal Spray

On January 30, 2026, PrimeGene announced that it had formally entered into a cooperation agreement with Jumpcan Pharmaceutical Group Co., Ltd. (“Jumpcan”), establishing a strategic partnership for the Class 1 innovative drug pumicitinib nasal spray. Under the terms of the agreement, PrimeGene will receive upfront and research and development milestone payments totaling up to RMB 100 million, while Jumpcan will obtain exclusive commercialization rights for the product in Greater China (including mainland China, Hong Kong, Macau, and Taiwan).

This collaboration will further strengthen the company’s pipeline of innovative drugs for immune and inflammatory diseases, accelerate the clinical development, indication expansion, and commercialization of this product, and enable patients to benefit more rapidly from novel, breakthrough therapies.

Li Yuliang, Chairman and General Manager of PrimeGene, stated:We look forward to establishing a partnership with Jumpcan to deliver high-quality innovative medicines to more patients. Pumeicitinib Nasal Spray offers significant differentiated advantages in the treatment of allergic rhinitis. We are confident in our future collaboration and anticipate achieving greater success through the joint efforts of both teams.

Cao Wei, General Manager of Jumpcan, stated:We are delighted to enter into a strategic partnership with PrimeGene. Jumpcan focuses on mid-to-long-term development strategies and market demands, dedicated to providing patients with a diverse range of innovative therapeutic drugs. There remains a significant unmet need among patients with allergic rhinitis, and we believe that PrimeGene’s pimecimetinib nasal spray can offer more effective treatment options for a broader population of allergic rhinitis patients.

Pumicitinib is a self-developed JAK1/2 inhibitor with full intellectual property rights, designed for the treatment of allergic rhinitis. It has the potential to become the world’s first JAKi nasal spray, offering a novel and breakthrough therapeutic option for patients with allergic rhinitis. Following approval by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration to conduct clinical trials, Pumicitinib nasal spray has completed multiple Phase I/II clinical studies and is currently undergoing Phase III clinical trials.

PrimeGene is an innovative pharmaceutical company focused on immune and inflammatory diseases, guided by unmet clinical needs, and distinguished by its expertise in topical formulations. Leveraging a seasoned R&D team, the company has established a leading innovative drug development platform, with a pipeline covering therapeutic areas such as dermatology, respiratory medicine, and ophthalmology. Its core products include Class 1 innovative drugs with global leadership potential, such as pimecixitinib gel for atopic dermatitis, pimecixitinib nasal spray for allergic rhinitis, PG-033 tablets for pruritus, PG-018 tablets for autoimmune kidney disease, and PG-040 eye drops for glaucoma.